Mimicking the action of Sex Hormone Binding Globulin (SHBG) effectively reduces ectopic fat, fibrosis and inflammation. Endolipid Tx is developing two novel peptides with validated efficacy - in vivo PoC: EDL6D for NASH and EDL3D for Cellulite/Slimming.

NASH is a growing and underserved disease. Endolipid Tx is developing EDL6D, an in vivo effective peptide that may offer a treatment opportunity for NASH with a novel and differentiated mechanism of action.

Cellulite and Slimming are poorly attended pathologies with scarce therapeutic innovation in the last 10 years. Endolipid Tx is developing EDL81, a peptide with a innovative mode of action and proven in vitro and in vivo efficacy in reducing ectopic fat in Cellulite and Slimming.

ENDOLIPID THERAPEUTICS

Org chart

Teams

Offices